{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:28:47Z","timestamp":1787624927589,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41375-020-0767-3","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T16:02:43Z","timestamp":1582819363000},"page":"2648-2659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk"],"prefix":"10.1038","volume":"34","author":[{"given":"F.","family":"Ferrer-Mar\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B.","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bellosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Cuenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"J. C.","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fernandez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Garc\u00eda Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kerguelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. V.","family":"Fiallo-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"G\u00f3mez-Casares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Boqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Garc\u00eda-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Arrizabalaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cifuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Arcas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"de los Reyes-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Besses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Teruel-Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gonz\u00e1lez-Conejero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"GEMFIN Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"767_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.","journal-title":"Blood Cancer J"},{"key":"767_CR2","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840\u20136.","journal-title":"Blood"},{"key":"767_CR3","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129:680\u201392.","journal-title":"Blood"},{"key":"767_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21\u201330.","journal-title":"Blood Adv"},{"key":"767_CR5","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"767_CR6","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219\u201325.","journal-title":"Blood"},{"key":"767_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5:316\u201331.","journal-title":"Cancer Discov"},{"key":"767_CR8","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/leu.2016.12","volume":"30","author":"S Koschmieder","year":"2016","unstructured":"Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, et al. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;30:1018\u201324.","journal-title":"Leukemia"},{"key":"767_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","volume":"130","author":"P Bose","year":"2017","unstructured":"Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017;130:115\u201325.","journal-title":"Blood"},{"key":"767_CR10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883\u201399.","journal-title":"Cell"},{"key":"767_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri1703","volume":"5","author":"M Karin","year":"2005","unstructured":"Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749\u201359.","journal-title":"Nat Rev Immunol"},{"key":"767_CR12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1182\/blood.V128.22.1203.1203","volume":"128","author":"AD Chorzalska","year":"2016","unstructured":"Chorzalska AD, Morgan J, Treaba DO, Olszewski AJ, Kingston N, Cheng Y, et al. Bone marrow-specific loss of ABI1 induces myelofibrosis through a mechanism involving activation of NF\u03baB. Blood. 2016;128:1203.","journal-title":"Blood"},{"key":"767_CR13","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1158\/0008-5472.CAN-04-2339","volume":"65","author":"E Komura","year":"2005","unstructured":"Komura E, Tonetti C, Penard-Lacronique V, Chagraoui H, Lacout C, Lecouedic JP, et al. Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res. 2005;65:3281\u20139.","journal-title":"Cancer Res"},{"key":"767_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrm2619","volume":"10","author":"P Brodersen","year":"2009","unstructured":"Brodersen P, Voinnet O. Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol. 2009;10:141\u20138.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"767_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/jmcb\/mjr007","volume":"3","author":"X Ma","year":"2011","unstructured":"Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-kappaB signaling. J Mol cell Biol. 2011;3:159\u201366.","journal-title":"J Mol cell Biol"},{"key":"767_CR16","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1084\/jem.20101823","volume":"208","author":"MP Boldin","year":"2011","unstructured":"Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011;208:1189\u2013201.","journal-title":"J Exp Med"},{"key":"767_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.18632\/aging.100042","volume":"1","author":"D Bhaumik","year":"2009","unstructured":"Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, et al. MicroRNAs miR-146a\/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging. 2009;1:402\u201311.","journal-title":"Aging"},{"key":"767_CR18","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1073\/pnas.1105398108","volume":"108","author":"JL Zhao","year":"2011","unstructured":"Zhao JL, Rao DS, Boldin MP, Taganov KD, O\u2019Connell RM, Baltimore D. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA. 2011;108:9184\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"767_CR19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2007.07.009","volume":"130","author":"FR Greten","year":"2007","unstructured":"Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell. 2007;130:918\u201331.","journal-title":"Cell"},{"key":"767_CR20","doi-asserted-by":"crossref","unstructured":"Liu T, Zhang L, Joo D, Sun SC. NF-kappaB signaling in inflammation. Signal Transduct Target Ther. 2017;2 pii: 17023.","DOI":"10.1038\/sigtrans.2017.23"},{"key":"767_CR21","doi-asserted-by":"publisher","first-page":"12481","DOI":"10.1073\/pnas.0605298103","volume":"103","author":"KD Taganov","year":"2006","unstructured":"Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006;103:12481\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"767_CR22","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.exphem.2007.08.020","volume":"35","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, Ponziani V, et al. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol. 2007;35:1708\u201318.","journal-title":"Exp Hematol"},{"key":"767_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nm.2054","volume":"16","author":"DT Starczynowski","year":"2010","unstructured":"Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med. 2010;16:49\u201358.","journal-title":"Nat Med"},{"key":"767_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/gene.2011.84","volume":"13","author":"SE Lofgren","year":"2012","unstructured":"Lofgren SE, Frostegard J, Truedsson L, Pons-Estel BA, D\u2019Alfonso S, Witte T, et al. Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun. 2012;13:268\u201374.","journal-title":"Genes Immun"},{"key":"767_CR25","doi-asserted-by":"publisher","first-page":"7269","DOI":"10.1073\/pnas.0802682105","volume":"105","author":"K Jazdzewski","year":"2008","unstructured":"Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2008;105:7269\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"767_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/ATVBAHA.112.300251","volume":"33","author":"YJ Jeon","year":"2013","unstructured":"Jeon YJ, Kim OJ, Kim SY, Oh SH, Oh D, Shin BS, et al. Association of the miR-146a, miR-149, miR-196a2, and miR-499 polymorphisms with ischemic stroke and silent brain infarction risk. Arterioscler Thromb Vasc Biol. 2013;33:420\u201330.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"767_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1160\/TH14-01-0092","volume":"112","author":"V Roldan","year":"2014","unstructured":"Roldan V, Arroyo AB, Salloum-Asfar S, Manzano-Fernandez S, Garcia-Barbera N, Marin F, et al. Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost. 2014;112:781\u20138.","journal-title":"Thromb Haemost"},{"key":"767_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437\u20138.","journal-title":"Leukemia"},{"key":"767_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"767_CR30","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"767_CR31","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2353\/jmoldx.2006.050130","volume":"8","author":"M Lay","year":"2006","unstructured":"Lay M, Mariappan R, Gotlib J, Dietz L, Sebastian S, Schrijver I, et al. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagnostics. 2006;8:330\u20134.","journal-title":"J Mol Diagnostics"},{"key":"767_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","volume":"97","author":"A Senin","year":"2018","unstructured":"Senin A, Fernandez-Rodriguez C, Bellosillo B, Camacho L, Longaron R, Angona A, et al. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Ann Hematol. 2018;97:443\u201351.","journal-title":"Ann Hematol"},{"key":"767_CR33","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379\u201390.","journal-title":"N Engl J Med"},{"key":"767_CR34","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jmoldx.2013.07.006","volume":"15","author":"LV Furtado","year":"2013","unstructured":"Furtado LV, Weigelin HC, Elenitoba-Johnson KS, Betz BL. Detection of MPL mutations by a novel allele-specific PCR-based strategy. J Mol Diagnostics. 2013;15:810\u20138.","journal-title":"J Mol Diagnostics"},{"key":"767_CR35","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/bioinformatics\/btl268","volume":"22","author":"X Sole","year":"2006","unstructured":"Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928\u20139.","journal-title":"Bioinformatics"},{"key":"767_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cncr.21645","volume":"106","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006;106:631\u20135.","journal-title":"Cancer"},{"key":"767_CR37","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1365-2141.2009.07804.x","volume":"146","author":"A Alvarez-Larran","year":"2009","unstructured":"Alvarez-Larran A, Bellosillo B, Martinez-Aviles L, Saumell S, Salar A, Abella E, et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol. 2009;146:504\u20139.","journal-title":"Br J Haematol"},{"key":"767_CR38","unstructured":"Klein J, Moeschberger ML. Survival analysis: techniques for censored and truncated data. 2nd ed. New York: Springer Nature; 2010."},{"key":"767_CR39","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"767_CR40","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"767_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-8722-5-13","volume":"5","author":"C Labbaye","year":"2012","unstructured":"Labbaye C, Testa U. The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. J Hematol Oncol. 2012;5:13.","journal-title":"J Hematol Oncol"},{"key":"767_CR42","doi-asserted-by":"publisher","first-page":"E7140","DOI":"10.1073\/pnas.1706833114","volume":"114","author":"N Magilnick","year":"2017","unstructured":"Magilnick N, Reyes EY, Wang WL, Vonderfecht SL, Gohda J, Inoue JI, et al. miR-146a-Traf6 regulatory axis controls autoimmunity and myelopoiesis, but is dispensable for hematopoietic stem cell homeostasis and tumor suppression. Proc Natl Acad Sci USA. 2017;114:E7140\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"767_CR43","doi-asserted-by":"crossref","unstructured":"Su YL, Wang X, Mann M, Adamus TP, Wang D, Moreira DF, et al. Myeloid cell-targeted miR-146a mimic inhibits NF-kB-driven inflammation and leukemia progression in vivo. Blood. 2019;135:167\u2013180.","DOI":"10.1182\/blood.2019002045"},{"key":"767_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-4-1","volume":"4","author":"H Votavova","year":"2011","unstructured":"Votavova H, Grmanova M, Dostalova Merkerova M, Belickova M, Vasikova A, Neuwirtova R, et al. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J Hematol Oncol. 2011;4:1.","journal-title":"J Hematol Oncol"},{"key":"767_CR45","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-018-0088-y","volume":"32","author":"E Masselli","year":"2018","unstructured":"Masselli E, Carubbi C, Cambo B, Pozzi G, Gobbi G, Mirandola P, et al. The -2518 A\/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity. Leukemia. 2018;32:2266\u201370.","journal-title":"Leukemia"},{"key":"767_CR46","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30:431\u20138.","journal-title":"Leukemia"},{"key":"767_CR47","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356\u201363.","journal-title":"J Clin Oncol"},{"key":"767_CR48","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ajh.23295","volume":"87","author":"R Vaidya","year":"2012","unstructured":"Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87:1003\u20135.","journal-title":"Am J Hematol"},{"key":"767_CR49","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","volume":"130","author":"KE Panteli","year":"2005","unstructured":"Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005;130:709\u201315.","journal-title":"Br J Haematol"},{"key":"767_CR50","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s13238-013-2084-3","volume":"4","author":"Y Fan","year":"2013","unstructured":"Fan Y, Mao R, Yang J. NF-kappaB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein & Cell. 2013;4:176\u201385.","journal-title":"Protein & Cell"},{"key":"767_CR51","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1182\/blood-2017-06-780882","volume":"130","author":"EM Pietras","year":"2017","unstructured":"Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood. 2017;130:1693\u20138.","journal-title":"Blood"},{"key":"767_CR52","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1038\/leu.2017.137","volume":"31","author":"N Stickel","year":"2017","unstructured":"Stickel N, Hanke K, Marschner D, Prinz G, Kohler M, Melchinger W, et al. MicroRNA-146a reduces MHC-II expression via targeting JAK\/STAT signaling in dendritic cells after stem cell transplantation. Leukemia. 2017;31:2732\u201341.","journal-title":"Leukemia"},{"key":"767_CR53","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","volume":"111","author":"LT Lam","year":"2008","unstructured":"Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111:3701\u201313.","journal-title":"Blood"},{"key":"767_CR54","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/blood-2018-05-848408","volume":"132","author":"A Chorzalska","year":"2018","unstructured":"Chorzalska A, Morgan J, Ahsan N, Treaba DO, Olszewski AJ, Petersen M, et al. Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. Blood. 2018;132:2053\u201366.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0767-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0767-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0767-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T08:06:11Z","timestamp":1650528371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0767-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0767-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was partially funded by Novartis International (CINC424AES05T).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}